A critical function for type I interferons in cancer immunoediting

Nature Immunology

Volumn 6, Issue 7, 2005, Pages 722-729

  Dunn, Gavin P ^a   Bruce, Allen T ^a   Sheehan, Kathleen C F ^a   Shankaran, Vijay ^a   Uppaluri, Ravindra ^a   Bui, Jack D ^a   Diamond, Mark S ^a   Koebel, Catherine M ^a   Arthur, Cora ^a   White, J Michael ^a   Schreiber, Robert D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CARCINOGEN; GAMMA INTERFERON; 3 METHYLCHOLANTHRENE; ALPHA BETA INTERFERON RECEPTOR; DNA BINDING PROTEIN; INTERFERON RECEPTOR; MEMBRANE PROTEIN; RAG2 PROTEIN, MOUSE; V(D)J RECOMBINATION ACTIVATING PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER TRANSPLANTATION; CONTROLLED STUDY; HEMATOPOIETIC CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; ANIMAL; EXPERIMENTAL NEOPLASM; HEMATOPOIESIS; IMMUNOLOGY; MOUSE MUTANT; RADIATION CHIMERA; SARCOMA; TUMOR ESCAPE;

ANIMALS; DNA-BINDING PROTEINS; HEMATOPOIESIS; INTERFERON-ALPHA; MEMBRANE PROTEINS; METHYLCHOLANTHRENE; MICE; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; RADIATION CHIMERA; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; SARCOMA; TUMOR ESCAPE;

EID: 22144465860     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni1213     Document Type: Article

References (42)

1. Shankaran, V. et al. IFN-γ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410, 1107-1111 (2001).
2. Dunn, G.P. et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998 (2002).
3. Dunn, G.P., Old, L.J. & Schreiber, R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329-360 (2004).
4. Dunn, G.P., Old, L.J. & Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137-148 (2004).
5. Dighe, A.S., Richards, E., Old, L.J. & Schreiber, R.D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors. Immunity 1, 447-456 (1994).
6. Kaplan, D.H. et al. Demonstration of an interferon-γ-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. USA 95, 7556-7561 (1998).
7. Ikeda, H., Old, L.J. & Schreiber, R.D. The roles of IFN-γ in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 13, 95-109 (2002).
8. + T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl. Acad. Sci. USA 96, 8633-8638 (1999).
9. Fallarino, F. & Gajewski, T.F. Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stall. J. Immunol. 163, 4109-4113 (1999).
10. Gresser, I. et al. Injection of mice with antibody to interferon enhances the growth of transplantable murine tumors. J. Exp. Med. 158, 2095-2107 (1983).
11. Gresser, I., Bandu, M.T. & Brouty-Boye, D. Interferon and cell division. IX. Interferon-resistant L1210 cells: characteristics and origin. J. Natl. Cancer Inst. 52, 553-559 (1974).
12. Affabris, E. et al. Molecular mechanisms of action of interferons in the Friend virus-induced leukemia cell system. Haematologica 72, 76-78 (1987).
13. Gresser, I. et al. Antibody to mouse interferon α/β abrogates resistance to the multiplication of Friend erythroleukemia cells in the livers of allogeneic mice. J. Exp. Med. 168, 1271-1291 (1988).
14. Belardelli, F., Ferrantini, M., Proietti, E. & Kirkwood, J.M. Interferon-α in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13, 119-134 (2002).
15. Qin, Z., Kim, H.J., Hennme, J. & Blankenstein, T. Inhibition of methylcholanthrene-induced carcinogenesis by an interferon-γ receptor-dependent foreign body reaction. J. Exp. Med. 195, 1479-1490 (2002).
16. Dighe, A.S., Farrar, M.A. & Schreiber, R.D. Inhibition of cellular responsiveness to interferon-γ (IFN-γ) induced by overexpression of inactive forms of the IFN-γ receptor. J. Biol. Chem. 268, 10645-10653 (1993).
17. + T Cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN-γ receptor expression by nonhematopoietic cells. Immunity 12, 677-686 (2000).
18. Le Bon, A. & Tough, D.F. Links between innate and adaptive immunity via type I Interferon. Curr. Opin. Immunol. 14, 432-436 (2002).
19. Gallucci, S., Lolkema, M. & Matzinger, P. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5, 1249-1255 (1999).
20. Montoya, M. et al. Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood 99, 3263-3271 (2002).
21. + T cells stimulated by virus-induced type I interferon. Nat. Immunol. 4, 1009-1015 (2003).
22. Le Bon, A. et al. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14, 461-470 (2001).
23. Wu, J. & Lanier, L.L. Natural killer cells and cancer. Adv. Cancer Res. 90, 127-156 (2003).
24. Sato, K. et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-α/β. Eur. J. Immunol. 31, 3138-3146 (2001).
25. Marrack, P., Kappler, J. & Mitchell, T. Type I interferons keep activated T cells alive. J. Exp. Med. 189, 521-530 (1999).
26. + T cells in vivo by IL-15. Immunity 8, 591-599 (1998).
27. Takaoka, A. et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature 424, 516-523 (2003).
28. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997).
29. Tough, D.F. Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation. Leuk. Lymphoma 45, 257-264 (2004).
30. Colonna, M., Krug, A. & Cella, M. Interferon-producing cells: on the front line in immune responses against pathogens. Curr. Opin. Immunol. 14, 373-379 (2002).
31. Colonna, M., Trinchieri, G. & Liu, Y.J. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 5, 1219-1226 (2004).
32. Taniguchi, T. & Takaoka, A. A weak signal for strong responses: interferon-α/β revisited. Nat. Rev. Mol. Cell Biol. 2, 378-386 (2001).
33. Soos, J.M. & Szente, B.E. Type I interferons, in The Cytokine Handbook Vol. 1 (eds. Lotz, M.T. & Thomson, A.W.) 549-566 (Academic Press, 2003).
34. Enzler, T. et al. Deficiencies of GM-CSF and interferon γ link inflammation and cancer. J. Exp. Med. 197, 1213-1219 (2003).
35. Lesinski, G.B. et al. The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse. J. Clin. Invest. 112, 170-180 (2003).
36. Belardelli, F., Gresser, I., Maury, C. & Maunoury, M.T. Antitumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant Friend leukemia cells. I. Int. J. Cancer 30, 813-820 (1982).
37. + Tcells. Nat. Immunol. 3, 549-557 (2002).
38. Liu, F., Song, Y. & Liu, D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6, 1258-1266 (1999).
39. Zhang, G., Budker, V. & Wolff, J.A. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. 10, 1735-1737 (1999).
40. Sheehan, K.C. et al. Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75. J. Exp. Med. 181, 607-617 (1995).
41. Kondo, M. et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu. Rev. Immunol. 21, 759-806 (2003).
42. Pear, W.S. et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92, 3780-3792 (1998).